Hua Medicine

Hua Medicine (Shanghai) Ltd. develops and commercializes drugs for diabetes in China. Its lead product is HuaTangNing (Dorzagliatin or HMS5552), an oral treatment for Type 2 Diabetes (T2D). The company is also studying Dorzagliatin in combinations with Metformin, Sitagliptin, Empagliflozin, GLP1RA, small molecule GLP-1, and insulin, as well as a second-generation glucokinase (GK) inhibitor, a GK NAM, and an mGLUR5 negative allosteric modulator (NAM). Incorporated in 2011, it is headquartered in Shanghai, China.